Laevadosin in Treatment of the Duchenne Type of Muscular Dystrophy: Preliminary Results of a Double-blind Controlled Trial

Abstract

Laevadosin, a mixture of nucleotides and nucleosides, when administered to patients with the Duchenne type of muscular dystrophy over a six-week period did not produce any observable benefits when compared with a placebo. The results were based on objective assessment of alterations in muscle power and changes in serum creatine kinase levels. The drug may be found to be of value after a more prolonged period of treatment and follow-up, but until the results of such an extended trial are known the routine administration of this remedy to patients with muscular dystrophy is not recommended. © 1964, British Medical Journal Publishing Group. All rights reserved.